Vanguard Group Inc. Lowers Position in Inspire Medical Systems, Inc. $INSP

Vanguard Group Inc. trimmed its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 1.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,953,170 shares of the company’s stock after selling 46,917 shares during the period. Vanguard Group Inc. owned approximately 0.10% of Inspire Medical Systems worth $272,371,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in INSP. Wasatch Advisors LP raised its holdings in shares of Inspire Medical Systems by 7.2% in the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Inspire Medical Systems by 68.7% in the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after purchasing an additional 528,404 shares during the last quarter. Deerfield Management Company L.P. increased its position in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the last quarter. State Street Corp raised its stake in Inspire Medical Systems by 2.3% in the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock valued at $133,780,000 after purchasing an additional 22,843 shares in the last quarter. Finally, M&T Bank Corp purchased a new stake in Inspire Medical Systems in the fourth quarter valued at approximately $85,871,000. 94.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

INSP has been the subject of a number of research reports. Bank of America reissued a “neutral” rating and issued a $53.00 price target on shares of Inspire Medical Systems in a research note on Tuesday. Jefferies Financial Group lowered their price objective on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating on the stock in a research report on Thursday, February 12th. Wolfe Research downgraded shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a report on Friday, February 13th. JPMorgan Chase & Co. cut their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Robert W. Baird reduced their target price on Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Inspire Medical Systems presently has an average rating of “Hold” and an average price target of $85.00.

Inspire Medical Systems Stock Performance

INSP stock opened at $44.28 on Friday. The company has a market capitalization of $1.28 billion, a PE ratio of 9.86, a price-to-earnings-growth ratio of 4.78 and a beta of 0.83. Inspire Medical Systems, Inc. has a one year low of $43.99 and a one year high of $161.88. The company’s 50 day moving average price is $56.01 and its two-hundred day moving average price is $78.97.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts predict that Inspire Medical Systems, Inc. will post 0.9 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.